verapamil has been researched along with mcn 5691 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almond, HR; Brannan, MD; Carmosin, RJ; Carson, JR; Flaim, SF; Gill, A; Gleason, MM; Keely, SL; Ludovici, DW; Pitis, PM | 1 |
| Brannan, MD; Damiano, BP; Flaim, SF; Gill, A; Stump, GL | 1 |
2 other study(ies) available for verapamil and mcn 5691
| Article | Year |
|---|---|
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
Topics: Alkynes; Amines; Animals; Calcium Channel Blockers; Coronary Circulation; Guinea Pigs; Hypertension; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Vasodilation | 1988 |
Cardiac electrophysiologic effects of McN-5691, a new calcium-channel blocking antihypertensive agent.
Topics: Action Potentials; Analysis of Variance; Animals; Antihypertensive Agents; Atrioventricular Node; Calcium Channel Blockers; Dogs; Dose-Response Relationship, Drug; Electrophysiology; Female; Heart; Male; Membrane Potentials; Myocardial Contraction; Papillary Muscles; Propylamines; Purkinje Fibers; Verapamil | 1990 |